Month: April 2022

Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting

HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutic candidates to address therapeutic resistance,...

Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology...

PROCEPT BioRobotics Corporation Announces Aetna and Independence Blue Cross Blue Shield Positive Coverage Decisions Regarding Aquablation Therapy for Men with Enlarged Prostates

REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing...

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor cellsPreclinical data shows proof-of-principle that...

New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022

Data support the continued development of OPGx-001 and OPGx-002 to address mutations in genes causing forms of Leber congenital amaurosisRALEIGH,...

error: Content is protected !!